Physician profile
Gregory L Walker
NPI 1366508301
$11,599.27
in general payments reported to CMS, 2019-2025
50 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $750 · 2020: $964 · 2021: $1,965 · 2022: $2,536 · 2023: $2,326 · 2024: $2,707 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,383.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,132.56 | 2019-2025 | Farxiga, Breztri, Lokelma |
| Horizon Therapeutics Plc | $1,249.64 | 2021-2023 | Krystexxa |
| Mallinckrodt Hospital Products INC. | $878.16 | 2021-2024 | Acthar |
| Amgen INC. | $691.10 | 2024-2025 | Krystexxa |
| Janssen Pharmaceuticals, INC | $675.55 | 2019-2022 | |
| Viiv Healthcare Company | $560.56 | 2020-2024 | Dovato, Apretude |
| Kowa Pharmaceuticals America, INC. | $502.85 | 2021-2024 | Zoryve, Livalo, Seglentis |
| Novo Nordisk INC | $438.54 | 2020-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $416.23 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $403.79 | 2021-2024 | |
| Astellas Pharma US INC | $315.46 | 2019-2025 | Veozah |
| Abbvie INC. | $308.43 | 2021-2023 | Ubrelvy, Qulipta |
| Akebia Therapeutics INC | $245.19 | 2021-2023 | Auryxia |
| Pfizer INC. | $240.21 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $193.95 | 2019-2022 |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $186.36 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Vifor Pharma, INC. | $148.58 | 2023 | Veltassa, Korsuva |
| Gilead Sciences, INC. | $144.16 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $140.27 | 2023-2024 | Quviviq |
| Bone Support INC. | $133.87 | 2022 | |
| Amarin Pharma, INC. | $129.08 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $124.00 | 2023-2024 | Gemtesa |
| Corcept Therapeutics | $123.65 | 2021-2024 | Korlym |
| Urovant Sciences INC | $113.64 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.39 | 2024 | Ofev, Jardiance |
| Phadia US INC. | $89.97 | 2024 | Immunocap |
| Lilly USA, LLC | $89.24 | 2021-2023 | Trulicity, Mounjaro |
| Fresenius USA Marketing, INC. | $76.71 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $72.96 | 2022-2024 | Jynarque |
| Travere Therapeutics, INC. | $57.77 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $56.16 | 2021-2022 | |
| Esperion Therapeutics, INC. | $53.81 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $46.24 | 2024 | Nuzyra |
| Hikma Pharmaceuticals USA | $39.95 | 2023 | Ryaltris, Kloxxado |
| Sunovion Pharmaceuticals INC. | $38.95 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $38.08 | 2024 | |
| Merck Sharp & Dohme LLC | $37.40 | 2019-2022 | |
| Verona Pharma, INC. | $32.72 | 2025 | Ohtuvayre |
| Cashflow Solutions, LLC | $32.54 | 2023 | Lympha Press Optimal Plus(US) Bt, Pcd-51 731a (US) - White, Pcd-52 737a (US) White |
| Protega Pharmaceutials INC | $32.11 | 2023-2024 | Roxybond |
| Ironwood Pharmaceuticals, INC | $30.72 | 2024 | |
| Exact Sciences Corporation | $23.24 | 2025 | Cologuard Collection Kit |
| Scpharmaceuticals INC. | $21.38 | 2025 | |
| Calliditas Therapeutics US INC. | $20.90 | 2022 | |
| Dexcom, INC. | $18.80 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $17.83 | 2021 | |
| Opko Pharmaceuticals, LLC | $16.85 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $16.31 | 2020 | |
| Allergan, INC. | $15.87 | 2019 | |
| Ardelyx, INC. | $13.54 | 2023 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.